RNA 기반 치료제 및 백신 시장 : 시장 분석 및 예측 - 유형별, 제품 유형별, 기술별, 컴포넌트별, 용도별, 프로세스별, 최종 사용자별, 솔루션별, 개발 단계별(-2035년)

The global RNA-Based Therapeutics and Vaccines Market is projected to grow from $0.3 billion in 2025 to $2.0 billion by 2035, at a compound annual growth rate (CAGR) of 24.6%. Growth is driven by advancements in biotechnology, increased prevalence of chronic diseases, and rising demand for personalized medicine, alongside regulatory support for innovative therapies. The RNA-Based Therapeutics and Vaccines Market is moderately consolidated, with mRNA vaccines leading the industry, followed by RNA interference therapeutics and antisense oligonucleotides. Demand is driven by applications in infectious diseases, oncology, and genetic disorders, supported by ongoing advancements in RNA science and delivery technologies. The competitive landscape includes established pharmaceutical companies alongside emerging biotechnology firms competing through innovation, product development, and pipeline expansion. Strategic collaborations, licensing agreements, mergers, and acquisitions remain common as companies strengthen research capabilities and broaden their portfolios. Partnerships between biotechnology companies, pharmaceutical manufacturers, and academic institutions continue to accelerate the development and commercialization of next-generation RNA-based therapeutics and vaccines.

Based on the Type segment, the RNA-Based Therapeutics and Vaccines market is segmented into mRNA-Based Therapeutics, siRNA-Based Therapeutics, miRNA-Based Therapeutics, RNA Interference (RNAi), Antisense RNA, and Others. Among these, mRNA-based therapeutics account for a significant share of the market due to their proven success in vaccine development, rapid design capabilities, and expanding applications in oncology and rare diseases. siRNA-based therapeutics are also witnessing strong growth, supported by increasing regulatory approvals and their ability to selectively silence disease-causing genes. Meanwhile, miRNA therapeutics, antisense RNA, and RNAi technologies continue to gain traction as research advances and clinical pipelines expand across multiple therapeutic areas.

Based on the Application segment, the RNA-Based Therapeutics and Vaccines market is segmented into Cancer, Infectious Diseases, Genetic Disorders, Cardiovascular Diseases, Neurological Disorders, and Others. Among these, infectious diseases represent a major application area, driven by the widespread adoption of mRNA vaccines and ongoing investments in pandemic preparedness. Cancer is another key segment, supported by the increasing development of personalized RNA-based immunotherapies and therapeutic vaccines. Additionally, the use of RNA technologies for treating genetic, cardiovascular, and neurological disorders is expanding as clinical research progresses and innovative RNA-based therapies demonstrate promising efficacy and safety in targeted disease management.

Geographical Overview

North America dominates the RNA-based therapeutics and vaccines market due to strong pharmaceutical innovation, extensive biotechnology research, and successful commercialization of mRNA technologies. Leading biotechnology companies, significant government funding, and robust clinical trial activity have accelerated product development. The region also benefits from advanced manufacturing capabilities, favorable regulatory support, and high healthcare expenditure. Increasing research into RNA therapeutics for oncology, rare diseases, and infectious diseases continues to expand market opportunities. Strong intellectual property protection and strategic partnerships further reinforce North America's leadership in this rapidly evolving therapeutic segment.

Asia-Pacific is anticipated to be the fastest-growing region in the RNA-based therapeutics and vaccines market owing to expanding biotechnology capabilities, rising investments in vaccine manufacturing, and increasing government support for advanced drug development. Countries such as China, Japan, South Korea, and India are strengthening research in RNA technologies through public-private collaborations. Growing demand for innovative therapies, expanding clinical research activities, and improving pharmaceutical manufacturing infrastructure are driving adoption. Rising healthcare expenditure and increasing focus on pandemic preparedness and precision medicine further contribute to strong regional market growth.

Key Trends and Drivers

Expansion of Advanced RNA Platforms Is Accelerating Therapeutic Innovation:

The increasing development of messenger RNA (mRNA), small interfering RNA (siRNA), and circular RNA platforms is a prominent trend in the RNA-based therapeutics and vaccines market. Advances in lipid nanoparticle delivery technologies and RNA stabilization techniques are improving therapeutic efficacy and expanding treatment possibilities beyond infectious diseases. Researchers are actively developing RNA-based therapies targeting oncology, rare diseases, cardiovascular disorders, and autoimmune conditions. The success of mRNA vaccines has accelerated broader investment in RNA research, supporting rapid innovation and diversification across multiple therapeutic applications.

Increasing Demand for Innovative Therapeutics Is Driving the Market Growth:

The growing demand for innovative treatment approaches and rapid vaccine development capabilities is a key driver of the RNA-based therapeutics and vaccines market. Increasing prevalence of chronic diseases, infectious outbreaks, and unmet medical needs has created strong demand for flexible therapeutic platforms capable of faster development compared to conventional biologics. Rising investments in biotechnology research, favorable government funding, expanding clinical pipelines, and continuous technological improvements in RNA synthesis and delivery systems are supporting commercialization. These factors are significantly accelerating the global adoption of RNA-based therapeutics and next-generation vaccines.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Technology
• 2.4 Key Market Highlights by Application
• 2.5 Key Market Highlights by End User
• 2.6 Key Market Highlights by Process
• 2.7 Key Market Highlights by Component
• 2.8 Key Market Highlights by Solutions
• 2.9 Key Market Highlights by Stage

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 mRNA-Based Therapeutics
  • 4.1.2 siRNA-Based Therapeutics
  • 4.1.3 miRNA-Based Therapeutics
  • 4.1.4 RNA Interference (RNAi)
  • 4.1.5 Antisense RNA
  • 4.1.6 Others
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 RNA Vaccines
  • 4.2.2 RNA Therapeutics
  • 4.2.3 RNA Delivery Systems
  • 4.2.4 RNA Synthesis Services
  • 4.2.5 Others
• 4.3 Market Size & Forecast by Technology (2020-2035)
  • 4.3.1 In Vitro Transcription
  • 4.3.2 Microarray
  • 4.3.3 RNA Sequencing
  • 4.3.4 RNA Interference Technology
  • 4.3.5 Others
• 4.4 Market Size & Forecast by Application (2020-2035)
  • 4.4.1 Cancer
  • 4.4.2 Infectious Diseases
  • 4.4.3 Genetic Disorders
  • 4.4.4 Cardiovascular Diseases
  • 4.4.5 Neurological Disorders
  • 4.4.6 Others
• 4.5 Market Size & Forecast by End User (2020-2035)
  • 4.5.1 Pharmaceutical Companies
  • 4.5.2 Biotechnology Companies
  • 4.5.3 Research Institutes
  • 4.5.4 Contract Research Organizations (CROs)
  • 4.5.5 Others
• 4.6 Market Size & Forecast by Process (2020-2035)
  • 4.6.1 Preclinical
  • 4.6.2 Clinical Trials
  • 4.6.3 Commercialization
  • 4.6.4 Others
• 4.7 Market Size & Forecast by Component (2020-2035)
  • 4.7.1 RNA Molecules
  • 4.7.2 Delivery Carriers
  • 4.7.3 Stabilizers
  • 4.7.4 Others
• 4.8 Market Size & Forecast by Solutions (2020-2035)
  • 4.8.1 Therapeutic Development
  • 4.8.2 Vaccine Development
  • 4.8.3 Drug Delivery Solutions
  • 4.8.4 Others
• 4.9 Market Size & Forecast by Stage (2020-2035)
  • 4.9.1 Discovery
  • 4.9.2 Preclinical Development
  • 4.9.3 Clinical Development
  • 4.9.4 Regulatory Approval
  • 4.9.5 Others

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Technology
    • 5.2.1.4 Application
    • 5.2.1.5 End User
    • 5.2.1.6 Process
    • 5.2.1.7 Component
    • 5.2.1.8 Solutions
    • 5.2.1.9 Stage
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Technology
    • 5.2.2.4 Application
    • 5.2.2.5 End User
    • 5.2.2.6 Process
    • 5.2.2.7 Component
    • 5.2.2.8 Solutions
    • 5.2.2.9 Stage
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Technology
    • 5.2.3.4 Application
    • 5.2.3.5 End User
    • 5.2.3.6 Process
    • 5.2.3.7 Component
    • 5.2.3.8 Solutions
    • 5.2.3.9 Stage
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Technology
    • 5.3.1.4 Application
    • 5.3.1.5 End User
    • 5.3.1.6 Process
    • 5.3.1.7 Component
    • 5.3.1.8 Solutions
    • 5.3.1.9 Stage
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Technology
    • 5.3.2.4 Application
    • 5.3.2.5 End User
    • 5.3.2.6 Process
    • 5.3.2.7 Component
    • 5.3.2.8 Solutions
    • 5.3.2.9 Stage
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Technology
    • 5.3.3.4 Application
    • 5.3.3.5 End User
    • 5.3.3.6 Process
    • 5.3.3.7 Component
    • 5.3.3.8 Solutions
    • 5.3.3.9 Stage
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Technology
    • 5.4.1.4 Application
    • 5.4.1.5 End User
    • 5.4.1.6 Process
    • 5.4.1.7 Component
    • 5.4.1.8 Solutions
    • 5.4.1.9 Stage
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Technology
    • 5.4.2.4 Application
    • 5.4.2.5 End User
    • 5.4.2.6 Process
    • 5.4.2.7 Component
    • 5.4.2.8 Solutions
    • 5.4.2.9 Stage
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Technology
    • 5.4.3.4 Application
    • 5.4.3.5 End User
    • 5.4.3.6 Process
    • 5.4.3.7 Component
    • 5.4.3.8 Solutions
    • 5.4.3.9 Stage
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Technology
    • 5.4.4.4 Application
    • 5.4.4.5 End User
    • 5.4.4.6 Process
    • 5.4.4.7 Component
    • 5.4.4.8 Solutions
    • 5.4.4.9 Stage
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Technology
    • 5.4.5.4 Application
    • 5.4.5.5 End User
    • 5.4.5.6 Process
    • 5.4.5.7 Component
    • 5.4.5.8 Solutions
    • 5.4.5.9 Stage
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Technology
    • 5.4.6.4 Application
    • 5.4.6.5 End User
    • 5.4.6.6 Process
    • 5.4.6.7 Component
    • 5.4.6.8 Solutions
    • 5.4.6.9 Stage
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Technology
    • 5.4.7.4 Application
    • 5.4.7.5 End User
    • 5.4.7.6 Process
    • 5.4.7.7 Component
    • 5.4.7.8 Solutions
    • 5.4.7.9 Stage
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Technology
    • 5.5.1.4 Application
    • 5.5.1.5 End User
    • 5.5.1.6 Process
    • 5.5.1.7 Component
    • 5.5.1.8 Solutions
    • 5.5.1.9 Stage
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Technology
    • 5.5.2.4 Application
    • 5.5.2.5 End User
    • 5.5.2.6 Process
    • 5.5.2.7 Component
    • 5.5.2.8 Solutions
    • 5.5.2.9 Stage
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Technology
    • 5.5.3.4 Application
    • 5.5.3.5 End User
    • 5.5.3.6 Process
    • 5.5.3.7 Component
    • 5.5.3.8 Solutions
    • 5.5.3.9 Stage
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Technology
    • 5.5.4.4 Application
    • 5.5.4.5 End User
    • 5.5.4.6 Process
    • 5.5.4.7 Component
    • 5.5.4.8 Solutions
    • 5.5.4.9 Stage
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Technology
    • 5.5.5.4 Application
    • 5.5.5.5 End User
    • 5.5.5.6 Process
    • 5.5.5.7 Component
    • 5.5.5.8 Solutions
    • 5.5.5.9 Stage
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Technology
    • 5.5.6.4 Application
    • 5.5.6.5 End User
    • 5.5.6.6 Process
    • 5.5.6.7 Component
    • 5.5.6.8 Solutions
    • 5.5.6.9 Stage
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Technology
    • 5.6.1.4 Application
    • 5.6.1.5 End User
    • 5.6.1.6 Process
    • 5.6.1.7 Component
    • 5.6.1.8 Solutions
    • 5.6.1.9 Stage
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Technology
    • 5.6.2.4 Application
    • 5.6.2.5 End User
    • 5.6.2.6 Process
    • 5.6.2.7 Component
    • 5.6.2.8 Solutions
    • 5.6.2.9 Stage
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Technology
    • 5.6.3.4 Application
    • 5.6.3.5 End User
    • 5.6.3.6 Process
    • 5.6.3.7 Component
    • 5.6.3.8 Solutions
    • 5.6.3.9 Stage
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Technology
    • 5.6.4.4 Application
    • 5.6.4.5 End User
    • 5.6.4.6 Process
    • 5.6.4.7 Component
    • 5.6.4.8 Solutions
    • 5.6.4.9 Stage
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Technology
    • 5.6.5.4 Application
    • 5.6.5.5 End User
    • 5.6.5.6 Process
    • 5.6.5.7 Component
    • 5.6.5.8 Solutions
    • 5.6.5.9 Stage

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Moderna
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 BioNTech
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 CureVac
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Arcturus Therapeutics
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Translate Bio
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Sarepta Therapeutics
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Alnylam Pharmaceuticals
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Ionis Pharmaceuticals
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Arrowhead Pharmaceuticals
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Dicerna Pharmaceuticals
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Silence Therapeutics
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 ProQR Therapeutics
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Regulus Therapeutics
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Marina Biotech
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Arbutus Biopharma
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Vir Biotechnology
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Beam Therapeutics
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Intellia Therapeutics
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Editas Medicine
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 CRISPR Therapeutics
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us